• Home
  • Media Center
  • Press Center
  • Media Focus

Media Focus

Samsung BioLogics’ CDO is lucrative strategy

San Francisco -- Samsung BioLogics’ newfound focus on small-scale contract development organization services will be the foundation for its plans to draw larger contract manufacturing organization deals, a top utive said Sunday.

“The CDO business will bring in 30 percent of CMO clients by 2030 and 50 percent by 2035,” Yang Eun-young, head of Samsung BioLogics’ CDO business team, told reporters a day ahead of the JP Morgan Healthcare Conference slated for Monday through Thursday.

CDO is the production of biologics ingredients for laboratory research and clinical trials. 

Once these ingredients get the green light for innovative new drug application and biologics license from health care authorities, they can be used on animals for preclinical trials and controlled group of humans. 

The batch is small at this point, and will become large and money-spinning when it crosses over to CMO deals, which involve commercialization of the drug.

“Being involved from the CDO stage allows us to foresee what CMO deals we are likely have in two or three years. 

With this foresight, we can build our fourth and fifth plants accordingly,” Yang said.

Using Samsung BioLogics’ CDO and CMO services is a win-win deal for biotech firms also. 

When a small company decides to move up from CDO level to CMO level production, changing facilities would require technology transfers which alone can cost a year’s time, he noted.

CDO is a tighter race against time than CMO. 

Which company proves drug efficacy and enters the market first is critical for its business. 

One or two months make all the difference, Yang said.

Aside from having the manufacturing capacity of 364,000 liters in a single generation, Samsung BioLogics is investing heavily in the latest technologies that would give it the necessary leverage to stay on top of the game.

It has reduced the number of months that it normally takes to bring a drug candidate from discovery to IND filing, from 18 to 14 months. 

It takes only 11 months for Samsung BioLogics to bring a drug candidate to the state it can be used for clinical phase 1 trials, Yang said, and the company is trying to shorten that further to nine months.

Samsung BioLogics is also the first from Asia to adopt Berkeley Light Beacon, which enables fully automated live cell isolation, selection and screening in nanopens. 

Cell line development finishes in three months with the use of Beacon -- earlier just the screening part took two months.

Yang said that Samsung BioLogics has benefited Korean biotechs over foreign firms so far, when it selects from the myriad business invitations.

“Epigyny within the Korean ecosystem has been a crucial mission for Samsung BioLogics since 2019,” said Yang, “We currently have 25:75 ratio of foreign and Korean clients for CDO partnerships -- but we will start picking up more global partners from 2021.”

Samsung BioLogics’ plants 1, 2 and 3 are able to cover advanced molecules, not to mention provide them whatever volume they request.

The CDMO currently has 45 CDO partnerships and has helped 47 novel drug approvals of its partnering firms. 

Innovative biotech firms like GI Innovation, Eutilex and ImmuneOnsia are a few of its partners.

GI Innovtion’s innovative drug designs were the toughest to produce -- but Samsung BioLogics was able to deliver what was asked: monoclonal antibody, fusion protein and bispecific fusion protein, among many others.

GI Innovation CEO Nam Su-youn said that having Samsung BioLogics as the manufacturer and supplier of the company’s innovative drugs was a favorable factor in its solid tumor pipeline licensing deal with Nanjing Simcere Dongyuan Pharmaceutical in November, worth 900 billion won ($779 million).

“Not only was Samsung BioLogics able to identify the best cell line out of thousands, it was also proactively helpful in answering our inquiries,” Nam said, “Simcere officials visited Samsung BioLogics’ plants many times during the business discussions. 

Having Samsung BioLogics as the manufacturer reduced the business risks.”

Nam and company co-founder Jang Myoung-ho are in San Francisco for the JP Morgan Healthcare Conference to hold business meetings with global big pharmas for developing combination cancer treatment with its cold tumor treatment pipeline GI-101 and its allergy treatment pipeline GI-301.

Half of what Samsung BioLogics three plants churn out now are antibody; the other half being specific antibody therapies. 

The company is yet to see economies of scale for gene and cell therapies but said it is keenly watching the global research and development trends.

Samsung BioLogics’ CEO Kim Tae-han and Vice President John Rim will make a presentation in the main track of JP Morgan Healthcare Conference on Wednesday.

The company started out in 2011 as a CMO business, but in 2019 it completed the “one-stop solution” services that cover the initial CDO and the later CRO services, providing a one-of-a-kind deal for novel drug development outsourcing.
San Francisco -- Samsung BioLogics’ newfound focus on small-scale contract development organization services will be the foundation for its plans to draw larger contract manufacturing organization deals, a top utive said Sunday.

“The CDO business will bring in 30 percent of CMO clients by 2030 and 50 percent by 2035,” Yang Eun-young, head of Samsung BioLogics’ CDO business team, told reporters a day ahead of the JP Morgan Healthcare Conference slated for Monday through Thursday.

CDO is the production of biologics ingredients for laboratory research and clinical trials. 

Once these ingredients get the green light for innovative new drug application and biologics license from health care authorities, they can be used on animals for preclinical trials and controlled group of humans. 

The batch is small at this point, and will become large and money-spinning when it crosses over to CMO deals, which involve commercialization of the drug.

“Being involved from the CDO stage allows us to foresee what CMO deals we are likely have in two or three years. 

With this foresight, we can build our fourth and fifth plants accordingly,” Yang said.

Using Samsung BioLogics’ CDO and CMO services is a win-win deal for biotech firms also. 

When a small company decides to move up from CDO level to CMO level production, changing facilities would require technology transfers which alone can cost a year’s time, he noted.

CDO is a tighter race against time than CMO. 

Which company proves drug efficacy and enters the market first is critical for its business. 

One or two months make all the difference, Yang said.

Aside from having the manufacturing capacity of 364,000 liters in a single generation, Samsung BioLogics is investing heavily in the latest technologies that would give it the necessary leverage to stay on top of the game.

It has reduced the number of months that it normally takes to bring a drug candidate from discovery to IND filing, from 18 to 14 months. 

It takes only 11 months for Samsung BioLogics to bring a drug candidate to the state it can be used for clinical phase 1 trials, Yang said, and the company is trying to shorten that further to nine months.

Samsung BioLogics is also the first from Asia to adopt Berkeley Light Beacon, which enables fully automated live cell isolation, selection and screening in nanopens. 

Cell line development finishes in three months with the use of Beacon -- earlier just the screening part took two months.

Yang said that Samsung BioLogics has benefited Korean biotechs over foreign firms so far, when it selects from the myriad business invitations.

“Epigyny within the Korean ecosystem has been a crucial mission for Samsung BioLogics since 2019,” said Yang, “We currently have 25:75 ratio of foreign and Korean clients for CDO partnerships -- but we will start picking up more global partners from 2021.”

Samsung BioLogics’ plants 1, 2 and 3 are able to cover advanced molecules, not to mention provide them whatever volume they request.

The CDMO currently has 45 CDO partnerships and has helped 47 novel drug approvals of its partnering firms. 

Innovative biotech firms like GI Innovation, Eutilex and ImmuneOnsia are a few of its partners.

GI Innovtion’s innovative drug designs were the toughest to produce -- but Samsung BioLogics was able to deliver what was asked: monoclonal antibody, fusion protein and bispecific fusion protein, among many others.

GI Innovation CEO Nam Su-youn said that having Samsung BioLogics as the manufacturer and supplier of the company’s innovative drugs was a favorable factor in its solid tumor pipeline licensing deal with Nanjing Simcere Dongyuan Pharmaceutical in November, worth 900 billion won ($779 million).

“Not only was Samsung BioLogics able to identify the best cell line out of thousands, it was also proactively helpful in answering our inquiries,” Nam said, “Simcere officials visited Samsung BioLogics’ plants many times during the business discussions. 

Having Samsung BioLogics as the manufacturer reduced the business risks.”

Nam and company co-founder Jang Myoung-ho are in San Francisco for the JP Morgan Healthcare Conference to hold business meetings with global big pharmas for developing combination cancer treatment with its cold tumor treatment pipeline GI-101 and its allergy treatment pipeline GI-301.

Half of what Samsung BioLogics three plants churn out now are antibody; the other half being specific antibody therapies. 

The company is yet to see economies of scale for gene and cell therapies but said it is keenly watching the global research and development trends.

Samsung BioLogics’ CEO Kim Tae-han and Vice President John Rim will make a presentation in the main track of JP Morgan Healthcare Conference on Wednesday.

The company started out in 2011 as a CMO business, but in 2019 it completed the “one-stop solution” services that cover the initial CDO and the later CRO services, providing a one-of-a-kind deal for novel drug development outsourcing.

SITE MAP

close
close

Samsung Biologics
Privacy Policy

초점받기 링크
Effective Date: [30Dec2019]

This Privacy Policy illustrates how Samsung Biologics ("we", “our”, “us”) use and protect information you provide through your use of this website (the "Website") or our customer inquiry and recruitment services (collectively the “Services”).

Please read this Privacy Policy carefully and feel free to contact us if you have any questions, using the contact information provided in the Contact Us section below.

Information we may collect from you
1.Customer Inquiry

When you fill out the “Contact Us Form” on our Website, we may collect the following types of information:

  • Customer Inquiry information include Category, Information we may collect from you.
    Category Information we may collect from you
    Contact Us Mandatory Name, E-mail Address, Company Name, Occupation, Country, Areas of Interest, Inquiries/Comments
    Optional Any additional information you provide including but not limited to the job title
    Customer Inquiry information include Category, Information we may collect from you.
    Category Information we may collect from you
    Contact Us Mandatory Name, E-mail Address, Company Name, Occupation, Country, Areas of Interest, Inquiries/Comments
    Optional Any additional information you provide including but not limited to the job title

    Access log and website usage information collected through cookies. For more information about how we use cookies on our Website, please see our Cookie Policy.

2.Recruitment

When you submit your application via “TalentPool” on our Website, we may collect the following types of information:

  • Recruitment infomation include Category, Information we may collect from you.
    Category Information we may collect from you
    Talent Pool Mandatory Name, E-mail Address, Country, Areas of Interest, Resume
    Optional Any additional information you provide including but not limited to personal profiles on SNS
    Application Form
    (in Korean)
    Mandatory Name, Date of Birth, Address, E-mail, Contact Number,
    Education History (Name of School, Major, Enrollment Year/Month, Graduation Year/Month, Location), Employment History (Employment Period, Company, Job Title, Job Scope, Major Task), Language, Miscellaneous (Military Status, Reason for Exemption, Veteran Status)
    Optional Any additional information you provide including but not limited to research career, special qualifications and licenses, personal profiles on SNS.
    Recruitment infomation include Category, Information we may collect from you.
    Category Information we may collect from you
    Talent Pool Mandatory Name, E-mail Address, Country, Areas of Interest, Resume
    Optional Any additional information you provide including but not limited to personal profiles on SNS
    Application Form
    (in Korean)
    Mandatory Name, Date of Birth, Address, E-mail, Contact Number,
    Education History (Name of School, Major, Enrollment Year/Month, Graduation Year/Month, Location), Employment History (Employment Period, Company, Job Title, Job Scope, Major Task), Language, Miscellaneous (Military Status, Reason for Exemption, Veteran Status)
    Optional Any additional information you provide including but not limited to research career, special qualifications and licenses, personal profiles on SNS.

*No sensitive information will be collected.

How we use your information
1.Customer Inquiry

We may use the information we collect from you to conduct certain services or activities such as replying to inquiries, maintaining business records, and conducting market research.

2.Recruitment

In order to proceed with recruitment process and communicate status/result of job application(s).

Sharing information with third parties

We will not disclose your information to third parties for their marketing or business purposes without your consent. However, notwithstanding the above, we may disclose your information to the following entities for recruitment purposes:

  • Educational institutions in your application.
    Your information (name, date of birth, major, admission year, graduation year, etc.) may be disclosed to educational institutions named in your application.
  • Previous companies you worked for and reference check vendors.
    Your information (i.e. name) may be disclosed to your previous workplaces and reference check vendors.
  • Service providers.
    We may disclose your information to companies that provide Services on our behalf. These entities cannot use your information for purposes other than providing Services on our behalf.
  • Other parties when required by law or as necessary to protect our rights.
    There may be instances where we disclose your information to other parties:
    • - to comply with legal obligations or legally binding disclosure orders (such as a search warrant or other court/regulatory order);
    • - to verify or ensure compliance with the terms and policies governing our Services; and
    • - to protect the rights, property, or safety of us or any of our business partners or customers.
  • Other parties in connection with corporate transactions.
    We may disclose your information to a third party as part of a merger or transfer, or in the event of a bankruptcy.
  • Other parties with your consent or at your direction.
    In addition to the disclosures described in this Privacy Policy, we may disclose information about you to third parties when you consent to or request such disclosure.
Your Rights

To the extent permitted under applicable law(s), you may ask us to return, destroy, or correct any inaccuracies regarding your personal information. You may also ask us to restrict or limit our use of your personal information unless such restriction or limitation prevents us from complying with applicable law(s) or meeting a legal obligation.

However, your rights above may be limited in cases where your request would disclose personal information of a third party or where such a request would infringe the rights of a third party (including our rights) or if you ask us to delete information which we are required by law to preserve or have legitimate interests in retaining. Other relevant exemptions may exist under the GDPR and national laws. We will inform you of the relevant exemptions when responding to your request. To make such a request concerning your rights set forth herein, please refer to the Contact Us section below.

International Transfer of Information

We are a company based in Korea, and your use of our Website and Services will involve the transfer, storage, and processing of your personal information in Korea. Please note that the information protection laws and other applicable laws of countries outside the European Economic Area (“EEA”), to which your information may be transferred, might not be as comprehensive as those in your country. We will take appropriate measures, in compliance with applicable law, to ensure that your personal information remains protected. Such measures include the use of EU Standard Contractual Clauses to safeguard the transfer of information outside of the EEA or other methods. For more information, please contact us at privacy.bio@samsung.com.

Data Retention

We will retain your personal information for a reasonable period of time that enables us to communicate with you, to provide you with Services, to maintain business records for audit purposes, to meet recordkeeping requirements under applicable law(s), to defend or bring any legal claims and to deal with any queries or complaints you may have.

Keeping Your Information Secure

We have put in place reasonable measures to safeguard the information we collect in connection with the Services. However, please note that although reasonable steps will be taken to protect your information, no website, internet transmission, computer system or wireless connection is 100% secure from any and all potential threats.

Personal Information – Children under the age of 13

The Services are designed for general audience and are not intended or directed to children.

For US Residents Only

In connection with the Services, we will not knowingly solicit or collect personal information from children under the age of 13. In the event we do collect such personal information inadvertently or unknowingly and we later learn about it, we will promptly delete such information. If you believe that children under the age of 13 may have provided personal information to us, please contact us using the Contact Us section of this Privacy Policy.

If You are an individual resident in the EU

We process your personal information on the legal grounds that the processing is :

  • Necessary for the performance of contractual obligation(s) between you and us, for example if we’re providing service(s) that you have requested;
  • Necessary for compliance with our legal obligations;
  • Necessary for our legitimate interests, such as preparing our communications to you and continuing to develop and improve our services; or
  • With your consent or at your direction.

If you do not provide certain information to us, we may, in some circumstances, be unable to comply with our obligations or provide you with the services that you request. We will inform you of the implications of not providing certain information.

As set forth in the “Your rights” section, you are entitled, in accordance with applicable law, to object to or request restriction of processing your personal information, and to request access to, correction of, or deletion of your personal information. When we use your information on the basis of your consent, you have the right to withdraw such a consent at any time. Any requests should be submitted in writing to the address listed below in the “Contact Us” section. You also have the right to file a complaint with data protection authorities.

Contact Us

If you have any questions about this Privacy Policy, please contact us using the details below.

- Contact : 032-455-9829

- Email : privacy.bio@samsung.com

Changes to this Privacy Policy

We may update this Privacy Policy from time to time. When we update the Privacy Policy, we will revise the “Effective Date” above and post the new Privacy Policy with a new date. We recommend that you review the Privacy Policy each time you visit our Website to stay informed of our most current practices and policies.

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION